| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1986PNAS...83.1911M |
| P356 | DOI | 10.1073/PNAS.83.6.1911 |
| P932 | PMC publication ID | 323194 |
| P698 | PubMed publication ID | 3006077 |
| P5875 | ResearchGate publication ID | 20150358 |
| P2093 | author name string | H Mitsuya | |
| S Broder | |||
| P2860 | cites work | Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS) | Q22242256 |
| 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro | Q24609215 | ||
| Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS | Q28262859 | ||
| Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate | Q28336184 | ||
| Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS | Q29614260 | ||
| Pharmacological inhibition of infectivity of HTLV-III in vitro. | Q30403335 | ||
| Neurological complications of acquired immune deficiency syndrome: Analysis of 50 patients | Q33477021 | ||
| Serological Analysis of a Subgroup of Human T-Lymphotropic Retroviruses (HTLV-III) Associated with AIDS | Q34054955 | ||
| Antibodies Reactive with Human T-Lymphotropic Retroviruses (HTLV-III) in the Serum of Patients with AIDS | Q34055350 | ||
| Effect of 2',3'-dideoxythymidine-5'-triphosphate on HeLa cell in vitro DNA synthesis: evidence that DNA polymerase alpha is the only polymerase required for cellular DNA replication | Q36171014 | ||
| Monoclonal antibodies specific for p24, the major core protein of human T-cell leukemia virus type III. | Q37526575 | ||
| Selective Tropism of Lymphadenopathy Associated Virus (LAV) for Helper-Inducer T Lymphocytes | Q39140204 | ||
| Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. | Q39255396 | ||
| Inhibition of the activity of DNA polymerase α by 2′,3′-dideoxythymidine 5′-triphosphate | Q39267674 | ||
| Further characterization of a cell-free system for measuring replicative and repair DNA synthesis with cultured human fibroblasts and evidence for the involvement of DNA polymeraseain DNA repair | Q39701653 | ||
| A Pathogenic Retrovirus (HTLV-III) Linked to AIDS | Q40111961 | ||
| Involvement of DNA polymerase alpha in simian virus 40 DNA replication | Q40140581 | ||
| Involvement of eucaryotic deoxyribonucleic acid polymerases .alpha. and .gamma. in the replication of cellular and viral deoxyribonucleic acid | Q40257569 | ||
| Effects of 2?,3?-dideoxynucleosides on mammalian cells and viruses | Q42817621 | ||
| Transfusion-associated acquired immunodeficiency syndrome. Evidence for persistent infection in blood donors | Q45207989 | ||
| Functional Properties of Antigen-Specific T Cells Infected by Human T-Cell Leukemia-Lymphoma Virus (HTLV-I) | Q45804258 | ||
| Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes | Q45806031 | ||
| RNA-directed DNA polymerase of Rous sarcoma virus: initiation of synthesis with 70 S viral RNA as template | Q45819261 | ||
| Direction of polymerization by the avian myeloblastosis virus deoxyribonucleic acid polymerase | Q45821119 | ||
| HTLV-III infection in brains of children and adults with AIDS encephalopathy | Q48536178 | ||
| Inhibition by 2′,3′-dideoxythymidine of retroviral infection of mouse and human cells | Q53578509 | ||
| Prevalence of Antibodies to Lymphadenopathy-Associated Retrovirus in African Patients with AIDS | Q54134707 | ||
| Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. | Q55245135 | ||
| Role of DNA polymerase gamma in adenovirus DNA replication. Mechanism of inhibition by 2',3'-dideoxynucleoside 5'-triphosphates | Q64381558 | ||
| Enzymatic synthesis of deoxyribonucleic acid. XXXIV. Termination of chain growth by a 2',3'-dideoxyribonucleotide | Q68604365 | ||
| Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome | Q69857527 | ||
| Evidence that DNA polymerases alpha and beta participate differentially in DNA repair synthesis induced by different agents | Q72652239 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| infectivity | Q1662346 | ||
| P304 | page(s) | 1911-5 | |
| P577 | publication date | 1986-03-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides | |
| P478 | volume | 83 |
| Q28316326 | (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro |
| Q41271237 | 2',3'-Dideoxycytidine metabolism in a new drug-resistant cell line |
| Q28316183 | 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcri |
| Q37191116 | 3'-Azido-3'-deoxythymidine-induced reduction in the ability of uninfected CD4-expressing cells to participate in syncytium formation |
| Q59417811 | 3′--Cyano-3′-deoxythymidine |
| Q28368392 | 4'-Acylated thymidine 5'-triphosphates: a tool to increase selectivity towards HIV-1 reverse transcriptase |
| Q44846323 | 5-Aza-cytosine derivative chemotherapy in AIDS. |
| Q42383177 | 6-Benzyl-sulfanyl-9H-purine |
| Q37784514 | A 40-Year Journey in Search of Selective Antiviral Chemotherapy* |
| Q63198380 | A New stereospecific synthesis of [3.1.0]bicyclic cyclopropano analog of 2'3'-dideoxyuridine |
| Q44636435 | A nonlinear three-compartment model for the administration of 2',3'-dideoxycytidine by using red blood cells as bioreactors |
| Q35849253 | A screen in Escherichia coli for nucleoside analogs that target human immunodeficiency virus (HIV) reverse transcriptase: coexpression of HIV reverse transcriptase and herpes simplex virus thymidine kinase |
| Q28335926 | Activities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro |
| Q28361285 | Adenallene and cytallene: acyclic-nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro |
| Q37242308 | Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription |
| Q26771734 | An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014 |
| Q28379270 | An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine |
| Q52405179 | An optimal time control problem for the administration of 2',3'-dideoxycytidine by using red blood cells as bioreactors. |
| Q36634858 | Anabolism and Mechanism of Action of Ro24-5098, an Isomer of 2',3'-Dideoxyadenosine (ddA) with Anti-HIV Activity |
| Q73501556 | Analysis of various nucleosides in plasma using solid phase extraction and high-performance liquid chromatography with UV detection |
| Q41121788 | Anti-HIV active naphthyl analogues of HEPT and DABO. |
| Q39683244 | Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production |
| Q30617425 | Anti-human immunodeficiency virus activities of nucleosides and nucleotides: correlation with molecular electrostatic potential data |
| Q28333679 | Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog |
| Q33977295 | Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. |
| Q43946677 | Antiretroviral activity in a marine red alga: reverse transcriptase inhibition by an aqueous extract of Schizymenia pacifica |
| Q71828771 | Antiretroviral therapy |
| Q44036228 | Antiretroviral therapy and immunologic reconstitution in AIDS. |
| Q38287902 | Antiretroviral therapy. |
| Q35322871 | Antiretroviral therapy: reverse transcriptase inhibition |
| Q36650619 | Antisense phosphorothioate oligodeoxynucleotides targeted to the vpr gene inhibit human immunodeficiency virus type 1 replication in primary human macrophages |
| Q40055204 | Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses |
| Q99727225 | Antiviral Drug Discovery To Address the COVID-19 Pandemic |
| Q35114114 | Antiviral activities of isometric dideoxynucleosides of D- and L-related stereochemistry |
| Q73332715 | Antiviral activities of various water and methanol soluble substances isolated from Ganoderma lucidum |
| Q40874319 | Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. |
| Q35366050 | Antiviral therapy for human immunodeficiency virus infections |
| Q39152916 | Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date |
| Q38709585 | Antiviral therapy in human immunodeficiency virus infection |
| Q40487963 | Antiviral therapy in human immunodeficiency virus infections. Current status (Part II). |
| Q36070394 | Antiviral therapy: current concepts and practices |
| Q35118261 | Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol |
| Q38815225 | Antivirals against animal viruses. |
| Q27755387 | Approved Antiviral Drugs over the Past 50 Years |
| Q60219892 | Asymmetric synthesis of enantiomerically pure 4′-fluoroalkyl-2,3′-dideoxy nucleosides |
| Q34614908 | Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides |
| Q37926590 | Central role of mitochondria in drug-induced liver injury |
| Q36060912 | Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study |
| Q45860339 | Characterization of reverse transcriptase from feline immunodeficiency virus |
| Q41505879 | Chemotherapeutic Options in HIV Infection |
| Q40487397 | Clinical pharmacology of zidovudine and other 2?,3?-dideoxynucleoside analogues |
| Q37859395 | Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations |
| Q30400060 | Combinatorial approaches to the prevention and treatment of HIV-1 infection |
| Q39782113 | Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases |
| Q40534064 | Comparative study of non nucleoside inhibitors with HIV-1 reverse transcriptase based on 3D-QSAR and docking |
| Q33757004 | Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides |
| Q28318354 | Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine |
| Q46703802 | Computational studies and drug design for HIV-1 reverse transcriptase inhibitors of 3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) analogs |
| Q54049611 | Concepts for the design of anti-HIV nucleoside prodrugs for treating cephalic HIV infection. |
| Q64998377 | Construction of an isonucleoside on a 2,6-dioxobicyclo[3.2.0]-heptane skeleton. |
| Q45859981 | Contribution of multiple rounds of viral entry and reverse transcription to expression of human immunodeficiency virus type 1. A quantitative kinetic study |
| Q33860214 | Correlation between preferred sugar ring conformation and activity of nucleoside analogues against human immunodeficiency virus |
| Q36634845 | Correlation of Molecular Conformation and Activity of Reverse Transcriptase Inhibitors |
| Q35174403 | Correlations Between theIn VitroandIn VivoActivity of Anti-HIV Agents: Implications for Future Drug Deyelopment |
| Q36279758 | Crystallization and preliminary structural analysis of Bacillus subtilis adenylosuccinate lyase, an enzyme implicated in infantile autism |
| Q38366289 | Curious discoveries in antiviral drug development: the role of serendipity |
| Q34390189 | Current status of antiretroviral therapies |
| Q36548703 | Current status of antiretroviral therapy |
| Q28334680 | Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro |
| Q28369684 | Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells |
| Q36634833 | DNA Polymerases versus HIV Reverse Transcriptase in AIDS Therapy |
| Q44295306 | Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection |
| Q38651297 | Design of some nucleic acid antimetabolites: expectations and reality |
| Q46215386 | Designing CD4 immunoadhesins for AIDS therapy |
| Q69850402 | Determination of 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine and 2',3'-dideoxycytidine in biological samples |
| Q58126816 | Determination of 2′,3′-Dideoxyinosine in Plasma by High Performance Liquid Chromatography |
| Q68079445 | Determination of 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, 3'-fluoro-3'-deoxythymidine and 2',3'-dideoxyinosine in biological samples by high-performance liquid chromatography |
| Q33978294 | Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry |
| Q33933498 | Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics |
| Q35174341 | Development of Inhibitors of Reverse Transcriptase and Protease as Therapeutics Against HIV Infection |
| Q54034689 | Development of novel nucleoside analogues for use against drug resistant strains of HIV-1. |
| Q37034610 | Development of protease inhibitors and the fight with drug-resistant HIV-1 variants |
| Q35255870 | Didanosine |
| Q34547322 | Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis |
| Q28327854 | Didanosine therapy in patients intolerant of or failing zidovudine therapy |
| Q35530740 | Didanosine, a new antiretroviral drug. A review |
| Q35331251 | Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection |
| Q43514070 | Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection |
| Q52066454 | Dideoxycytidine, an anti-HIV drug, selectively inhibits growth but not phosphatidylcholine metabolism in neuroblastoma and glioma cells. |
| Q45860738 | Dideoxyinosine in Children with Symptomatic Human Immunodeficiency Virus Infection |
| Q28361679 | Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1 |
| Q39828007 | Different patterns of inhibition of avian myeloblastosis virus reverse transcriptase activity by 3'-azido-3'-deoxythymidine 5'-triphosphate and its threo isomer |
| Q33754889 | Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells |
| Q33978880 | Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells |
| Q28323369 | Differential inhibitory effects of some catechin derivatives on the activities of human immunodeficiency virus reverse transcriptase and cellular deoxyribonucleic and ribonucleic acid polymerases |
| Q28323433 | Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases |
| Q34349394 | Differential susceptibility of retroviruses to nucleoside analogues |
| Q92691723 | Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication |
| Q36672092 | Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals |
| Q45853176 | Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine |
| Q28341307 | Disposition of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in mice |
| Q35802085 | Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro |
| Q28338199 | Effect of retinoic acid on the replication of human immunodeficiency virus in HTLV-I-positive MT-4 cells |
| Q36821541 | Effect of temperature on the high-performance liquid chromatographic separation of the anti-HIV agents, didanosine and stavudine |
| Q42614912 | Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation |
| Q28379020 | Effects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in mice |
| Q35854248 | Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA |
| Q40937654 | Effects of cycloSal-d4TMP derivatives in H9 cells with induced AZT resistance phenotype |
| Q45772570 | Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays |
| Q44742776 | Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus |
| Q38612672 | Efficacy of antiviral chemotherapy for retrovirus-infected cats: What does the current literature tell us? |
| Q40975672 | Efficient Incorporation of Anti-HIV Deoxynucleotides by Recombinant Yeast Mitochondrial DNA Polymerase |
| Q35264706 | Emergence of aminoglycoside resistance genes aadA and aadE in the genus Campylobacter |
| Q36150601 | Emerging anti-HIV drugs |
| Q34438680 | Enantiomerically pure phosphonated carbocyclic 2'-oxa-3'-azanucleosides: synthesis and biological evaluation. |
| Q39730794 | Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients |
| Q40191379 | Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. |
| Q28378655 | Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1 |
| Q33554232 | Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants |
| Q34508874 | Extract of Prunella vulgaris spikes inhibits HIV replication at reverse transcription in vitro and can be absorbed from intestine in vivo |
| Q36353945 | Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages |
| Q40484511 | Future Therapies in the Management of Critically Ill, AIDS Patients |
| Q40589839 | Future of prodrugs in antiviral therapy |
| Q28316971 | Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3'-deoxythymidine |
| Q41994844 | Guidelines for the care of children and adolescents with HIV infection. Retroviral therapy and clinical trials for HIV-infected children |
| Q56786269 | HIV Reverse Transcriptase Inhibitors |
| Q35853012 | HIV-1 antiretroviral drug therapy |
| Q36674581 | HIV-Specific Treatment |
| Q43787255 | Hamao Umezawa Memorial Award Lecture: "An Odyssey in the Viral Chemotherapy Field". |
| Q36646145 | Hematologic Effects of AIDS Therapies |
| Q30687083 | High performance liquid chromatography analysis of 9-(2',3'-dideoxy-2'beta-fluoro-D-threo-penta furanosyl) adenine and its metabolite in human plasma using solid-phase extraction on a polyfluorinated reversed stationary phase |
| Q69848206 | High-performance liquid chromatographic determination of 2',3'-dideoxycytidine and 3'-azido-3'-deoxythymidine in plasma using a column-switching technique |
| Q67291481 | High-performance liquid chromatographic method for analysis of 2',3'-dideoxyinosine in human body fluids |
| Q68078066 | High-performance liquid chromatographic method for the analysis of 2',3'-dideoxycytidine in human plasma |
| Q34548972 | Highly active antiretroviral therapy and viral response in HIV type 2 infection |
| Q28375823 | Homologues of isomeric dideoxynucleosides as potential antiviral agents: synthesis of isodideoxynucleosides with a furanethanol sugar moiety |
| Q45786698 | Human Immunodeficiency Virus Type 1 Infection Requires Reverse Transcription of Nascent Viral RNA |
| Q28342825 | Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone |
| Q40067319 | Human immunodeficiency virus type 1 NL4-3 replication in four T-cell lines: rate and efficiency of entry, a major determinant of permissiveness |
| Q34350730 | Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells |
| Q33804495 | Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain |
| Q28367543 | Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine |
| Q28323712 | Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase |
| Q41375344 | Immunomodulatory and antiviral activities of 2',3'-dideoxy-beta-L-cytidine and 2',3'-dideoxy-beta-L-5-fluorocytidine |
| Q23915942 | Immunotoxicity of 2',3'-dideoxyinosine in female B6C3F1 mice |
| Q42801263 | Improved uptake and retention of lipophilic prodrug to improve treatment of HIV. |
| Q33395770 | In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model |
| Q40547788 | In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes |
| Q28378709 | In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine |
| Q39819064 | In vitro bone marrow toxicity of nucleoside analogs against human immunodeficiency virus |
| Q39989119 | In vitro evaluation of experimental agents for anti-HIV activity |
| Q28318476 | In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations |
| Q28323307 | In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors |
| Q28324338 | In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine |
| Q28379471 | Increased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyurea |
| Q33848825 | Induction of rapid and extensive beta-chemokine synthesis in macrophages by human immunodeficiency virus type 1 and gp120, independently of their coreceptor phenotype |
| Q35263031 | Induction of the SOS response in Escherichia coli by azidothymidine and dideoxynucleosides |
| Q27485071 | Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies |
| Q28367580 | Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides |
| Q28369350 | Inhibition of beta-globin gene expression by 3'-azido-3'-deoxythymidine in human erythroid progenitor cells |
| Q28359853 | Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides |
| Q43915080 | Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate |
| Q34264407 | Inhibition of immune functions by antiviral drugs |
| Q28359652 | Inhibition of infectivity of human immunodeficiency virus by a novel nucleoside, oxetanocin, and related compounds |
| Q35610321 | Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. |
| Q44438129 | Inhibition of wild-type human immunodeficiency virus and reverse transcriptase inhibitor-resistant variants by Phyllanthus amarus |
| Q28342785 | Inhibitors of HIV-1 Protease |
| Q24619823 | Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus |
| Q37783043 | Initial clinical experience with dideoxynucleosides as single agents and in combination therapy |
| Q36678586 | Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites |
| Q63198365 | Intramolecular cyclization-trapping of carbon radicals by olefins as means to functionalize 2′- and 3′-carbons in β-D-nucleosides |
| Q40509090 | Isothiazole derivatives as novel HIV replication inhibitors. |
| Q71743065 | L- and D-enantiomers of 2',3'-dideoxycytidine 5'-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity |
| Q34610200 | Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro |
| Q43288824 | Looking back in 2009 at the dawning of antiviral therapy now 50 years ago an historical perspective |
| Q40626125 | Management of antiretroviral drug therapy in human immunodeficiency virus infection |
| Q28360109 | Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent |
| Q28343606 | Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants |
| Q35122784 | Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription |
| Q40672674 | Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives |
| Q54337692 | Metabolism in human leukocytes of anti-HIV dideoxypurine nucleosides. |
| Q34402837 | Metabolism of 2',3'-dideoxyinosine (ddI) in human blood |
| Q41644125 | Metabolism of 4'-azidothymidine. A compound with potent and selective activity against the human immunodeficiency virus |
| Q41833765 | Metabolism, mitochondrial uptake and toxicity of 2', 3'-dideoxycytidine. |
| Q63198392 | Michael addition reactions of α β-ene-3′-phenylselenone of uridine. New synthesis of 2′,3′-dideoxy-ribo-aziridino-, 2′,3′-dideoxy-2′, 3′-ribo-cyclopropyl- & 2,2′-O-anhydro-3′-deoxy-3′-amino uridine derivatives |
| Q40793195 | Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro |
| Q43797776 | Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC). |
| Q28379011 | Mode of inhibition of HIV reverse transcriptase by 2-hexaprenylhydroquinone, a novel general inhibitor of RNA-and DNA-directed DNA polymerases |
| Q38291464 | Mode of inhibition of HIV-1 reverse transcriptase by polyacetylenetriol, a novel inhibitor of RNA- and DNA-directed DNA polymerases |
| Q41699823 | Modulation of Metabolism and Anti-HIV-1 Activity of Purine 2′,3′-Dideoxynucleosides by IMP Dehydrogenase Inhibitors |
| Q33981149 | Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents |
| Q24684152 | Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy |
| Q30658869 | Mutagenesis of key residues identifies the connection subdomain of HIV-1 reverse transcriptase as the site of inhibition by heme |
| Q55242852 | Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins. |
| Q24542513 | Nucleoside Oxidase, a Hydrogen Peroxide-Forming Oxidase, from Flavobacterium meningosepticum. |
| Q39692591 | Pathogenesis of human immunodeficiency virus infection and prospects for control |
| Q45880071 | Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys |
| Q40088469 | Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus |
| Q52462768 | Pharmacokinetics of 2',3'-Dideoxycytidine after High-Dose Administration to Rats |
| Q67995492 | Pharmacokinetics of 2',3'-dideoxyadenosine in dogs |
| Q40086226 | Pharmacokinetics of 2',3'-dideoxyinosine (BMY-40900), a new anti-human immunodeficiency virus agent, after administration of single intravenous doses to beagle dogs |
| Q35115096 | Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys |
| Q38511971 | Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus |
| Q35012107 | Pharmacological and biological aspects of basic research on nucleoside-based reverse transcriptase inhibitors |
| Q35576980 | Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I |
| Q73179125 | Pharmacophoric features of nucleosidic HIV-1RT inhibitors |
| Q36355185 | Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines |
| Q28368058 | Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice |
| Q28359877 | Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents |
| Q88786491 | Phosphoramidates and phosphonamidates (ProTides) with antiviral activity |
| Q28361672 | Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus |
| Q28340188 | Phosphorothioate and cordycepin analogues of 2',5'-oligoadenylate: inhibition of human immunodeficiency virus type 1 reverse transcriptase and infection in vitro |
| Q72420656 | Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses |
| Q28340356 | Phosphorylation of 3'-azido-2',3'-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5'-triphosphate |
| Q28343672 | Polycitone A, a novel and potent general inhibitor of retroviral reverse transcriptases and cellular DNA polymerases |
| Q35128255 | Potent activity of 2'-beta-fluoro-2',3'-dideoxyadenosine against human immunodeficiency virus type 1 infection in hu-PBL-SCID mice. |
| Q33781391 | Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. |
| Q28377216 | Potentiation of the anti-HIV activity of zalcitabine and lamivudine by a CTP synthase inhibitor, 3-deazauridine |
| Q35820362 | Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription |
| Q42125891 | Production of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine from 2',3'-dideoxyuridine and the corresponding purine bases by resting cells of Escherichia coli AJ 2595. |
| Q42817123 | Productive infection of primary murine astrocytes, lymphocytes, and macrophages by human immunodeficiency virus type 1 in culture |
| Q34675778 | Progress in drug therapies for HIV infection |
| Q39828862 | Purification and characterization of an avian myeloblastosis and human immunodeficiency virus reverse transcriptase inhibitor, sulfated polysaccharides extracted from sea algae |
| Q24550164 | Purification, characterization, and gene cloning of purine nucleosidase from Ochrobactrum anthropi |
| Q68380573 | Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography |
| Q41176946 | Quantitative structure-activity relationship studies on anti-HIV-1 TIBO derivatives as inhibitors of viral reverse transcriptase |
| Q43857985 | Quantitative structure-activity relationship studies on some viral reverse transcriptase inhibitors acting as anti-HIV-1 agents |
| Q36690814 | RNase H activity associated with reverse transcriptase from feline immunodeficiency virus |
| Q42622850 | Randomized study of two doses of didanosine in children infected with human immunodeficiency virus |
| Q33681664 | Recent advances in antiviral therapy |
| Q28339853 | Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells |
| Q36889165 | Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry |
| Q22242815 | Reverse transcription of the HIV-1 pandemic |
| Q69357163 | Reversed-phase liquid chromatographic determination of 2',3'-dideoxycytidine in human blood samples |
| Q69448180 | Reversed-phase liquid chromatographic retention and selectivity surfaces. II. Deoxyribonucleosides |
| Q28361577 | Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro |
| Q28337829 | Ribavirin antagonizes the effect of azidothymidine on HIV replication |
| Q40208864 | Sensitive reverse transcriptase assay to detect and quantitate human immunodeficiency virus. |
| Q57637247 | Separation of individual antiviral nucleotide prodrugs from synthetic mixtures using cross-reactivity of a molecularly imprinted stationary phase |
| Q73991182 | Single dose and multiple dose pharmacokinetics of 2'-fluoro-2',3'-dideoxyadenosine and 2'-fluoro-2',3'-dideoxyinosine, anti-HIV agents, in rats |
| Q42284160 | Sodium benzylideneascorbate induces apoptosis in HIV-replicating U1 cells |
| Q34640420 | Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men. |
| Q28369425 | Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors. A basis for anti-HIV drug design |
| Q57082533 | Straightforward C-8 alkylation of adenosine analogues with tetraalkyltin reagents |
| Q38172146 | Strategies for antiviral therapy in AIDS. |
| Q63198374 | Structural studies on 1-(1-deoxy-β-d-psicofuranosyl)thymine |
| Q28342189 | Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1 |
| Q28620349 | Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases |
| Q28324621 | Substrate specificity of human deoxycytidine kinase toward antiviral 2prime;,3′-dideoxynucleoside analogs |
| Q41326195 | Suppression of immune responses by dendritic cells infected with HIV. |
| Q28367590 | Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors |
| Q28369111 | Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates |
| Q28340298 | Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidine |
| Q28338307 | Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro |
| Q28324208 | Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine |
| Q28326720 | Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro |
| Q38784732 | Synthesis and Anti-HIV-1 Evaluation of Some Novel MC-1220 Analogs as Non-Nucleoside Reverse Transcriptase Inhibitors. |
| Q56786419 | Synthesis and Antiviral Activity of Novel Fluorinated 2′,3′‐Dideoxynucleosides |
| Q38827914 | Synthesis and Biological Evaluation of 9-Deazaadenine 5'-Deoxy-6',6'-Difluoro-Carbocyclic C-Nucleoside Phosphonic Acid Derivatives |
| Q31442456 | Synthesis and antiviral activities of N-9-oxypurine 1,3-dioxolane and 1,3-oxathiolane nucleosides |
| Q42234101 | Synthesis and antiviral evaluation of novel 2',2'-difluoro 5'-norcarbocyclic phosphonic acid nucleosides as antiviral agents |
| Q51872819 | Synthesis and evaluation of novel 6',6'-difluoro 5'-deoxycarbocyclic phosphonic acid nucleosides as antiviral agents. |
| Q74577858 | Synthesis and structure determination of some oxadiazole-2-thione and triazole-3-thione galactosides |
| Q63198345 | Synthesis of 2′- and 3′-spiro-isoxazolidine derivatives of thymidine & their conversions to 2′,3′-dideoxy-2′,3′-didehydro-3′--substituted nucleosides by radical promoted fragmentation |
| Q59417727 | Synthesis of 2′-C-cyano-2′-deoxy- and 2′-C-cyano-2′,3′-dideoxy-β-d-arabinofuranosyl nucleosides |
| Q57771815 | Synthesis of 2′-Deoxy-1′-homo-N-nucleosides with Anti-Influenza Activity by Catalytic Methyltrioxorhenium (MTO)/H2O2Oxyfunctionalization |
| Q63761401 | Synthesis of 5-Homologous AZT and D4T Derivatives |
| Q56956811 | Synthesis of 6-dimethylaminopurine 2′,3′-dideoxynucleosides |
| Q38473352 | Synthesis of enantiomerically pure D- and L-bicyclo[3.1.0]hexenyl carbanucleosides and their antiviral evaluation |
| Q57167992 | Synthesis of iso-ddA, member of a novel class of anti-HIV agents |
| Q63198384 | Synthesis of new 2',3'-dideoxy-2',3'-α-fused-heterocyclic uridines, & some 2', 3'-ene-2'-substituted uridines from easily accessible 2',3'- ene-3'phenylselenonyl uridine |
| Q63198377 | Synthesis of new 2′, 3′-modified uridine derivatives from 2′,3′-ene-2′-phenylselenonyl uridine by Michael addition reactions |
| Q39667999 | Synthesis of novel acyclic nucleoside analogues with anti-retroviral activity |
| Q28368901 | Synthesis of sulfated oligosaccharide glycosides having high anti-HIV activity and the relationship between activity and chemical structure |
| Q36374005 | Synthesis, evaluation of anti-HIV-1 and anti-HCV activity of novel 2',3'-dideoxy-2',2'-difluoro-4'-azanucleosides |
| Q41015658 | Synthesis, in vitro anti-HIV activity, and biological stability of 5'-O-myristoyl analogue derivatives of 3'-fluoro-2',3'-dideoxythymidine (FLT) as potential bifunctional prodrugs of FLT. |
| Q40586859 | Synthesis, structural characterization and biological evaluation of 4'-C-methyl- and phenyl-dioxolane pyrimidine and purine nucleosides. |
| Q38292564 | Template-competitive inhibitors of HIV-1 reverse transcriptase: design, synthesis and inhibitory activity |
| Q40089234 | The ProTide Prodrug Technology: From the Concept to the Clinic |
| Q24655011 | The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic |
| Q90356090 | The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold |
| Q52323442 | The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. |
| Q39563538 | The future of antiviral chemotherapy |
| Q45411974 | The incorporation of nucleoside analogs by human immunodeficiency virus type 1 reverse transcriptase decreases in the presence of polyamines |
| Q28323456 | The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivatives |
| Q40662335 | The molecular biology of HIV. Insights into pathogenesis and targets for therapy. |
| Q41639874 | The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2‘,3‘-dideoxycytidine |
| Q28319933 | The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro |
| Q37698440 | The unabated synthesis of new nucleoside analogues with antiviral potential: a tribute to Morris J. Robins |
| Q40431573 | Therapeutic Approaches to HIV Infection Based on Virus Structure and the Host Pathogen Interaction |
| Q24652927 | Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin |
| Q42513231 | Transbuccal delivery of 2',3'-dideoxycytidine: in vitro permeation study and histological investigation |
| Q71198082 | Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation |
| Q33752846 | Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques |
| Q35232021 | Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects |
| Q33740357 | Treatment of human immunodeficiency virus infections |
| Q37770831 | Twenty-five years of translational medicine in antiretroviral therapy: promises to keep |
| Q35900776 | Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2'3'-dideoxycytidine |
| Q43741841 | Understanding the mode of action of L-nucleosides as antiviral agents: a molecular modeling approach |
| Q35207285 | Update on didanosine |
| Q36822667 | Use of recombinant retroviruses to characterize the activity of antiretroviral compounds |
| Q34101462 | Vaccine and antiviral strategies against infections caused by human immunodeficiency virus. |
| Q35979700 | Validation of a High-Throughput Screening Assay for Identification of Adjunctive and Directly Acting Antimicrobials Targeting Carbapenem-Resistant Enterobacteriaceae |
| Q37034618 | Viral drug resistance and fitness. |
| Q24676814 | Visna virus as an in vitro model for human immunodeficiency virus and inhibition by ribavirin, phosphonoformate, and 2',3'-dideoxynucleosides |
| Q35156244 | Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS) |
| Q41494492 | Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection |
| Q40447103 | Zalcitabine. Clinical pharmacokinetics and efficacy. |
| Q43741855 | Zidovudine (AZT) resistance in H9 cells due to decreased TK expression is associated with hypermethylation of TK gene |
| Q28370101 | ddC- and 3TC-bis(SATE) monophosphate prodrugs overcome cellular resistance mechanisms to HIV-1 associated with cytidine kinase deficiency |
| Q28342341 | Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucl |
Search more.